ClinicalTrials.gg
Status unknownNCT02901652Updated Jul 18, 2019

NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome

An interventional study of noninvasive respiratory support devices in Prematurity and Respiratory Distress Syndrome, sponsored by Zekai Tahir Burak Women's Health Research and Education Hospital. Status unknown at 1 site in Turkey. Open to participants aged 1 Hour to 3 Days. Per ClinicalTrials.gov, last updated 2019-07-18.

Sponsored by Zekai Tahir Burak Women's Health Research and Education Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
1 Hour to 3 Days
Sex
All
01

Study summary

Purpose is to compare introduction of NIPPV (Nasal Intermittent Positive-Pressure Ventilation) and nBiPAP (Nasal Bi-level Positive Airway Pressure) in terms of mechanical ventilation (MV) need (non-invasive respiratory support failure) and surfactant need within the first 72 hours of life in preterm infants with Respiratory Distress Syndrome (RDS) at 26-30 weeks of gestation.

Read the detailed description

Purpose is to compare introduction of NIPPV and nBiPAP in terms of mechanical ventilation (MV) need (non-invasive respiratory support failure) and surfactant need within the first 72 hours of life in preterm infants with Respiratory Distress Syndrome (RDS) at 26-30 weeks of gestation.

Method

Primary Outcome Measures:

In NIPPV and BIPAP groups, comparison of mechanical ventilation (MV) need (non-invasive respiratory support failure) and surfactant need within the first 72 hours of life

Secondary Outcome Measures:

  • Compare patients' need of total duration of invasive and non-invasive respiratory support and the duration of free oxygen
  • Compare oxygen need in postnatal day 28 and week 36
  • Compare the presence and severity of BPD (Bronchopulmonary dysplasia)
  • Compare premature morbidities such as PDA (patent ductus arteriosus), IVH (intraventricular haemorrhage), NEC (necrotizing enterocolitis), ROP (retinopathy of prematurity)
  • Compare feeding intolerance, reaching birth weight and transition to full oral feeding time, hospitalization period
  • Compare their neurodevelopment in postnatal age 2

Study Design In NIPPV group; non-synchronous mode will be used, and they will be titrated between FiO2: 021-0.50 in a respiratory rate of 20-40 / min, peak inspiratory pressure (PIP): 15-20 end-expiratory pressure (PEEP):5-6 cm H2O and target oxygen saturation: 90-95 %. In nBiPAP group; they will be titrated between 021-0.50, in non-synchronized PEEP:6 H2O, pressure amplitude: 3 cm H2O, FiO2 target oxygen saturation of 90-95 %.

Under non-invasive respiratory support, in case of FiO2 is ≥ 0.40, surfactant will be given as early rescue therapy by means of non-invasive method (by using a thin catheter - take care method- while spontaneous breathing continues) in order to keep target oxygen saturation between 90-95 %. The second dose of surfactant will be given 6 hours after the first dose by means on non-invasive method in order to keep target oxygen saturation between 90-95 % in case of FiO2 need is ≥ 0.30.

Non-invasive respiratory support failure is set as follows:

  • FiO2 of ≥ 0.50 in order to keep oxygen saturation measured by pulse oximetry above 90 % and higher,
  • Apnea requiring more than 6 alerts in a 24 -hour period in 6 consecutive hours or more than 1 apnea requiring positive pressure ventilation,
  • Persistent acidosis; presence of pH \< 7.20 and PCO2 > 65 mmHg in two different blood gases drawn with an interval of at least 30 minutes or treatment-resistant metabolic acidosis,
  • Severe respiratory distress,
  • Pulmonary haemorrhage and cardiopulmonary arrest.
02

Conditions studied

  • Prematurity
  • Respiratory Distress Syndrome
03

In context

Premature Birth

2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.

This study's planned enrollment of 325 is above the median of 84 across 1,666 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Zekai Tahir Burak Women's Health Research and Education Hospital is the lead sponsor of 62 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Hour to 3 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infant with gestational age of 26 weeks 0 days and 29 weeks 6 days will be included.

Exclusion criteria

Exclusion Criteria:

  • Major congenital anomalies
  • Presence of cardiovascular instability
  • Intubation at admission to the NICU
  • Consent not provided or refused
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
325 participants (estimated)

Study arms

  • Active comparator
    NIPPV

    noninvasive respiratory support devices This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment.

    Device: noninvasive respiratory support devices

  • Active comparator
    BİPAP

    noninvasive respiratory support devices This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment.

    Device: noninvasive respiratory support devices

Interventions

  • Devicenoninvasive respiratory support devices
06

What researchers measure

Primary outcomes

  1. surfactant requirement

    surfactant requirement within the first 72 hours of life

    Time frame: 72 HOURS

07

Study locations

1 of 1 sites recruiting
  • Zekai Tahir Burak Maternity Teaching
    Ankara, 06230, Turkey
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02901652
Lead sponsor
Zekai Tahir Burak Women's Health Research and Education Hospital
Responsible party
Sponsor
First posted
Sep 15, 2016
Start date
Sep 2016
Primary completion
Sep 2019 (estimated)
Completion
Sep 30, 2019 (estimated)
Last update
Jul 18, 2019

Study contacts

Mehmet Büyüktiryaki, MD
Contact
mbuyuktiryaki@yahoo.com
+905054525576
Suna Oguz, MD
Contact
serifesuna@gmail.com
+90 3123065270
Suna Oğuz, MD
study director · Zekai Tahir Burak Women's Health Research and Education Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion